Valuation : Virbac

Market Cap 271.02Cr 314.52Cr 254.11Cr 231.97Cr 436.99Cr 30TCr 438.38Cr 3.01TCr 1.18TCr 15TCr 1.18TCr 1.16TCr 50TCr P/E 2026 *
15.9x
P/E 2027 * 14.4x
Enterprise Value 283.7Cr 329.23Cr 265.99Cr 242.81Cr 457.43Cr 31TCr 458.88Cr 3.16TCr 1.23TCr 16TCr 1.24TCr 1.21TCr 53TCr EV / Sales 2026 *
1.83x
EV / Sales 2027 * 1.69x
Free-Float
49.03%
Yield 2026 *
0.53%
Yield 2027 * 0.63%
1 week-2.57%
Current month-4.44%
1 month-6.52%
3 months-10.04%
6 months-12.24%
Current year-9.28%
1 week 322
Extreme 322
333
1 month 322
Extreme 322
349
3 years 241
Extreme 241
394.5
5 years 216.5
Extreme 216.5
441.5
10 years 101.68
Extreme 101.682
441.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.57%-3.87%+19.67% 314.52Cr
+3.09%-0.50%-50.55%-59.87% 3.2TCr
-1.55%+0.58%+31.39%+94.44% 1.2TCr
+2.32%+3.89%-16.64%+9.43% 403.73Cr
+0.15%-2.56%-3.43%+17.42% 314.52Cr
-0.63%+0.08%+48.77%+34.54% 205.07Cr
+0.42%+2.44%+14.86%+14.20% 197.12Cr
+3.63%+3.72%+1.62%+154.01% 152.95Cr
+0.58%-3.46%-22.84%-8.27% 116.75Cr
+1.62%+2.68%-9.46%-40.65% 104.57Cr
Average +1.07%+1.45%-1.02%+23.49% 655.02Cr
Weighted average by Cap. +1.65%+0.36%-19.84%-5.45%

Financials

2026 *2027 *
Net sales 155.09Cr 179.99Cr 145.42Cr 132.74Cr 250.07Cr 17TCr 250.86Cr 1.73TCr 673.13Cr 8.68TCr 675.75Cr 661.05Cr 29TCr 164.73Cr 191.17Cr 154.45Cr 140.99Cr 265.61Cr 18TCr 266.45Cr 1.83TCr 714.95Cr 9.22TCr 717.74Cr 702.13Cr 31TCr
Net income 17Cr 20Cr 16Cr 15Cr 28Cr 1.9TCr 28Cr 190.35Cr 74Cr 958.05Cr 75Cr 73Cr 3.18TCr 19Cr 22Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 210.85Cr 82Cr 1.06TCr 83Cr 81Cr 3.52TCr
Net Debt 13Cr 15Cr 12Cr 11Cr 20Cr 1.41TCr 21Cr 140.99Cr 55Cr 709.63Cr 55Cr 54Cr 2.35TCr 7.52Cr 8.72Cr 7.05Cr 6.43Cr 12Cr 833.61Cr 12Cr 84Cr 33Cr 420.8Cr 33Cr 32Cr 1.4TCr
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
-
Date Price Change
28/26/28 €322.50 0.00%
27/26/27 €322.50 -2.42%
26/26/26 €330.50 +0.76%
25/26/25 €328.00 -0.15%
24/26/24 €328.50 -0.76%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
323.50EUR
Average target price
411.88EUR
Spread / Average Target
+27.32%

Quarterly revenue - Rate of surprise